These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8504796)
21. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents. Steinborn B; Galas-Zgorzalewicz B Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. Steinborn B Rocz Akad Med Bialymst; 2005; 50 Suppl 1():9-15. PubMed ID: 16119616 [TBL] [Abstract][Full Text] [Related]
25. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Wolf P; May T; Tiska G; Schreiber G Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685 [TBL] [Abstract][Full Text] [Related]
26. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Sachdeo RC; Sachdeo SK; Walker SA; Kramer LD; Nayak RK; Doose DR Epilepsia; 1996 Aug; 37(8):774-80. PubMed ID: 8764818 [TBL] [Abstract][Full Text] [Related]
27. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. Muñoz JJ; De Salamanca RE; Diaz-Obregón C; Timoneda FL Br J Clin Pharmacol; 1990 Jun; 29(6):763-5. PubMed ID: 2378792 [TBL] [Abstract][Full Text] [Related]
28. Problem of spurious correlation in the evaluation of steady-state carbamazepine levels using metabolite data. van Belle G; Friel PN Ther Drug Monit; 1986; 8(2):177-83. PubMed ID: 3726931 [TBL] [Abstract][Full Text] [Related]
29. A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects. Larkin JG; McLellan A; Munday A; Sutherland M; Butler E; Brodie MJ Br J Clin Pharmacol; 1989 Mar; 27(3):313-22. PubMed ID: 2655682 [TBL] [Abstract][Full Text] [Related]
30. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Deckers CL; Hekster YA; Keyser A; van Lier HJ; Meinardi H; Renier WO Epilepsia; 2001 Nov; 42(11):1387-94. PubMed ID: 11879339 [TBL] [Abstract][Full Text] [Related]
31. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B; J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814 [TBL] [Abstract][Full Text] [Related]
32. Kinetic profile of carbamazepine in an adult Portuguese outpatient population. Almeida AM; Falcão AC; Sales F; Leitão F; Santos J; Costa IM; Caramona MM J Clin Pharm Ther; 1998 Aug; 23(4):315-21. PubMed ID: 9867316 [TBL] [Abstract][Full Text] [Related]
33. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism. Macphee GJ; Butler E; Brodie MJ Epilepsia; 1987; 28(3):286-94. PubMed ID: 3582293 [TBL] [Abstract][Full Text] [Related]
34. The 24 hour variation of salivary carbamazepine and carbamazepine-10,11-epoxide concentrations in children with epilepsy. Bäckman E; Dahlström G; Eeg-Olofsson O; Bertler A Pediatr Neurol; 1987; 3(6):327-30. PubMed ID: 3149473 [TBL] [Abstract][Full Text] [Related]
35. Iron supplements in nursing home patients associated with reduced carbamazepine absorption. Ahn JE; Bathena SPR; Brundage RC; Conway JM; Leppik IE; Birnbaum AK Epilepsy Res; 2018 Nov; 147():115-118. PubMed ID: 30327119 [TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. Pohlmann-Eden B; Marson AG; Noack-Rink M; Ramirez F; Tofighy A; Werhahn KJ; Wild I; Trinka E BMC Neurol; 2016 Aug; 16(1):149. PubMed ID: 27552848 [TBL] [Abstract][Full Text] [Related]
37. The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy. Patsalos PN; Russell-Jones D; Finnerty G; Sander JW; Shorvon SD Epilepsy Res; 1990 Apr; 5(3):235-9. PubMed ID: 2384079 [TBL] [Abstract][Full Text] [Related]
38. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491 [TBL] [Abstract][Full Text] [Related]
39. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation. Schäffler L; Bourgeois BF; Lüders HO Epilepsia; 1994; 35(1):195-8. PubMed ID: 8112245 [TBL] [Abstract][Full Text] [Related]
40. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy. Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]